Dianthus Therapeutics, Inc.
DNTH
Updated: 24/09/2026, 19:48:48
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
No summaries found.
- Share price
- $90.89
- Market cap
- $5.08B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Marino Garcia
- Employees
- 92
- IPO date
- 21/06/2018
- Beta
- 0.082
- Last dividend
- $0.00
- Day range
- $90.41 – $94.95
- 52-week range
- $32.22 – $117.88
- 1-day performance
- -2.73%
- 1-year performance
- 182.09%
- Current drawdown (1Y)
- -22.90%
- CIK
- 0001690585
- CUSIP
- 252828108
- ISIN
- US2528281080
- Created
- 07/12/2025, 03:38:05
- Last update
- 24/09/2026, 19:48:48
Track Dianthus Therapeutics, Inc. with an AI analyst
See which prediction-market events move DNTH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 19:12:12
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Seeking Alpha • STOCK • 30/05/2026, 12:06:23
Dianthus Therapeutics to Participate in Two Investor Conferences
GlobeNewsWire • STOCK • 26/05/2026, 18:01:00
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
GlobeNewsWire • STOCK • 19/05/2026, 17:00:00
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
GlobeNewsWire • STOCK • 06/05/2026, 00:57:00
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research • STOCK • 05/05/2026, 20:16:23
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
The Motley Fool • STOCK • 19/04/2026, 11:08:22
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
The Motley Fool • STOCK • 06/04/2026, 17:27:17
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Zacks Investment Research • STOCK • 01/04/2026, 06:55:37
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewsWire • STOCK • 12/03/2026, 17:01:00
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
GlobeNewsWire • STOCK • 10/03/2026, 23:54:00
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Seeking Alpha • STOCK • 10/03/2026, 15:08:54